Investor Presentaiton
Investor presentation
Full year 2018
Slide 19
Key take-aways - Full year 2018
.
Diabetes franchise grew 4% and Novo Nordisk retains world leader position with a market share of 27.9% (27.4% in 2017)
Insulin sales were flat and Novo Nordisk has expanded its volume market leader position to 46.4% insulin market share
(45.9% in 2017)
Diabetes
•
GLP-1 sales grew 18% and Novo Nordisk holds the market leader position with 46% value market share
Obesity
Oral semaglutide submission is expected in the USA around the end of Q1 2019, priority review voucher to be used
Obesity sales increased by 60% and accounted for 30% share of Novo Nordisk's sales growth. SaxendaⓇ is now launched in
41 countries
Biopharm
Financials
Outlook
Biopharm strategy execution on track: Biopharm sales broadly unchanged, progression of pipeline and complementary assets
added to the product portfolio
Sales growth of 5% driven by both International Operations (7% sales growth) and North America Operations (3% sales
growth). Sales growth driven by 18% GLP-1 sales growth and 60% obesity sales growth
Operating profit growth of 6% when adjusting for the severance costs and the priority review voucher
Sales growth in 2019 expected to be 2-5% with a positive currency impact of 2 percentage points
Operating profit growth in 2019 expected to be 2-6% with a positive currency impact of 4 percentage points
Long-term financial targets adjusted for OPAT/NOA from 125% to 80% and Cash to earnings from 90% to 85%
Note: Sales growth numbers are measured in local currenciesView entire presentation